Great Novel Therapeutics Biotech & Medicals (TPEX:7427)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
32.50
+0.85 (2.69%)
Mar 10, 2026, 1:59 PM CST

TPEX:7427 Ratios and Metrics

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Mar '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Market Capitalization
1,3591,4842,5621,823936-
Upgrade
Market Cap Growth
-25.21%-42.09%40.55%94.83%--
Upgrade
Enterprise Value
8688842,0631,731777-
Upgrade
Last Close Price
31.6532.2960.9752.0933.38-
Upgrade
PS Ratio
763.29880.65528.303376.081485.29-
Upgrade
PB Ratio
2.412.344.796.594.49-
Upgrade
P/TBV Ratio
2.532.455.076.987.81-
Upgrade
EV/Sales Ratio
-524.33425.313205.061233.73-
Upgrade
Debt / Equity Ratio
0.020.020.03---
Upgrade
Net Debt / Equity Ratio
-0.87-0.90-0.87-0.89-0.60-0.56
Upgrade
Net Debt / EBITDA Ratio
5.675.277.323.693.572.32
Upgrade
Net Debt / FCF Ratio
6.177.257.993.213.681.60
Upgrade
Asset Turnover
0.000.000.010.000.00-
Upgrade
Inventory Turnover
0.240.15----
Upgrade
Quick Ratio
28.9126.7729.9520.565.7912.64
Upgrade
Current Ratio
30.3227.4330.4720.875.8012.67
Upgrade
Return on Equity (ROE)
-14.21%-17.97%-15.04%-27.68%-21.80%-33.34%
Upgrade
Return on Assets (ROA)
-8.88%-11.51%-9.68%-16.58%-12.83%-17.66%
Upgrade
Return on Capital Employed (ROCE)
-16.10%-17.60%-12.10%-24.90%-17.50%-24.80%
Upgrade
Earnings Yield
-6.46%-7.07%-2.38%-3.68%-3.83%-
Upgrade
FCF Yield
-5.86%-5.32%-2.26%-4.23%-3.63%-
Upgrade
Buyback Yield / Dilution
-12.53%-13.60%-50.23%-14.54%-33.09%-16.83%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.